Vidara Therapeutics

Vidara Therapeutics was formed to acquire and develop pharmaceutical products to treat life-threatening diseases.

In June 2012, Greyrock Capital provided $3.0 million of subordinated debt and a $2.1 million equity co-investment to support the acquisition of a niche pharmaceutical product.